O	0	1	A
O	2	12	randomized
O	13	18	study
O	19	21	of
B-intervention	22	32	olanzapine
I-intervention	32	33	-
I-intervention	33	43	containing
O	44	50	versus
B-control	51	59	standard
I-control	60	70	antiemetic
I-control	71	79	regimens
O	80	83	for
O	84	87	the
O	88	98	prevention
O	99	101	of
B-condition	102	114	chemotherapy
I-condition	114	115	-
I-condition	115	122	induced
I-condition	123	129	nausea
I-condition	130	133	and
I-condition	134	142	vomiting
O	143	145	in
B-ethinicity	146	153	Chinese
O	154	160	breast
O	161	167	cancer
O	168	176	patients
O	176	177	.

O	178	190	Chemotherapy
O	190	191	-
O	191	198	induced
O	199	205	nausea
O	206	209	and
O	210	218	vomiting
O	219	220	(
O	220	224	CINV
O	224	225	)
O	226	229	are
O	230	241	distressing
O	242	250	symptoms
O	250	251	.

O	252	256	This
O	257	267	randomized
O	268	273	study
O	274	283	evaluated
O	284	287	the
O	288	298	antiemetic
O	299	309	efficacies
O	310	312	of
O	313	321	standard
O	322	332	antiemetic
O	333	340	regimen
O	341	345	with
O	345	346	/
O	346	353	without
O	354	364	olanzapine
O	364	365	.

O	366	374	Eligible
O	375	383	patients
O	384	388	were
B-eligibility	389	401	chemotherapy
I-eligibility	401	402	-
I-eligibility	402	407	naive
I-eligibility	408	415	Chinese
I-eligibility	416	422	breast
I-eligibility	423	429	cancer
I-eligibility	430	438	patients
I-eligibility	439	442	who
I-eligibility	443	447	were
I-eligibility	448	455	planned
I-eligibility	456	459	for
I-eligibility	460	461	(
I-eligibility	461	464	neo
I-eligibility	464	465	)
I-eligibility	465	473	adjuvant
I-eligibility	474	485	doxorubicin
I-eligibility	485	486	/
I-eligibility	486	502	cyclophosphamide
O	502	503	.

O	504	514	Antiemetic
O	515	522	regimen
O	523	526	for
O	527	530	all
O	531	538	studied
O	539	549	population
O	550	558	included
O	559	569	aprepitant
O	569	570	,
O	571	582	ondansetron
O	583	586	and
O	587	600	dexamethasone
O	600	601	;
O	602	610	patients
O	611	615	were
O	616	626	randomized
O	627	629	to
O	630	640	Olanzapine
O	641	642	(
O	642	646	with
O	647	657	olanzapine
O	657	658	)
O	659	661	or
O	662	670	Standard
O	671	675	arms
O	676	677	(
O	677	684	without
O	685	695	olanzapine
O	695	696	)
O	696	697	.

O	698	706	Patients
O	707	713	filled
O	714	716	in
O	717	721	self
O	721	722	-
O	722	730	reported
O	731	738	diaries
O	739	742	and
O	743	752	completed
O	753	759	visual
O	760	768	analogue
O	769	775	scales
O	776	779	for
O	780	786	nausea
O	786	787	,
O	788	790	as
O	791	795	well
O	796	798	as
O	799	809	Functional
O	810	816	Living
O	817	822	Index
O	822	823	-
O	823	829	Emesis
O	830	844	questionnaires
O	844	845	.

O	846	851	Blood
O	852	860	profiles
O	861	870	including
O	871	878	fasting
O	879	886	glucose
O	887	890	and
O	891	897	lipids
O	898	902	were
O	903	912	monitored
O	912	913	.

B-total-participants	914	917	120
O	918	926	patients
O	927	931	were
O	932	942	randomized
O	942	943	.

O	944	946	In
O	947	952	Cycle
O	953	954	1
O	955	966	doxorubicin
O	966	967	/
O	967	983	cyclophosphamide
O	983	984	,
O	985	988	the
O	989	999	Olanzapine
O	1000	1003	arm
O	1004	1007	had
O	1008	1021	significantly
O	1022	1028	higher
B-outcome	1029	1034	rates
I-outcome	1035	1037	of
I-outcome	1038	1039	"
I-outcome	1039	1047	Complete
I-outcome	1048	1056	Response
I-outcome	1056	1057	"
O	1058	1062	than
O	1063	1066	the
O	1067	1075	Standard
O	1076	1079	arm
O	1079	1080	:
B-iv-bin-percent	1081	1083	65
I-iv-bin-percent	1083	1084	.
I-iv-bin-percent	1084	1085	0
I-iv-bin-percent	1085	1086	%
O	1087	1089	vs
B-cv-bin-percent	1090	1092	38
I-cv-bin-percent	1092	1093	.
I-cv-bin-percent	1093	1094	3
I-cv-bin-percent	1094	1095	%
B-outcome	1096	1098	in
I-outcome	1099	1102	the
I-outcome	1103	1110	overall
I-outcome	1111	1117	period
O	1118	1119	(
O	1119	1120	p
O	1121	1122	=
O	1123	1124	0
O	1124	1125	.
O	1125	1129	0035
O	1129	1130	)
O	1130	1131	,
B-iv-bin-percent	1132	1134	70
I-iv-bin-percent	1134	1135	.
I-iv-bin-percent	1135	1136	0
I-iv-bin-percent	1136	1137	%
O	1138	1140	vs
B-cv-bin-percent	1141	1143	51
I-cv-bin-percent	1143	1144	.
I-cv-bin-percent	1144	1145	7
I-cv-bin-percent	1145	1146	%
B-outcome	1147	1149	in
I-outcome	1150	1153	the
I-outcome	1154	1159	acute
I-outcome	1160	1166	period
O	1167	1168	(
O	1168	1169	p
O	1170	1171	=
O	1172	1173	0
O	1173	1174	.
O	1174	1178	0397
O	1178	1179	)
O	1180	1183	and
B-iv-bin-percent	1184	1186	92
I-iv-bin-percent	1186	1187	.
I-iv-bin-percent	1187	1188	9
I-iv-bin-percent	1188	1189	%
O	1190	1192	vs
B-cv-bin-percent	1193	1195	74
I-cv-bin-percent	1195	1196	.
I-cv-bin-percent	1196	1197	2
I-cv-bin-percent	1197	1198	%
B-outcome	1199	1201	in
I-outcome	1202	1205	the
I-outcome	1206	1213	delayed
I-outcome	1214	1220	period
O	1221	1222	(
O	1222	1223	p
O	1224	1225	=
O	1226	1227	0
O	1227	1228	.
O	1228	1232	0254
O	1232	1233	)
O	1233	1234	.

O	1235	1245	Olanzapine
O	1246	1249	arm
O	1250	1254	also
O	1255	1258	had
O	1259	1272	significantly
O	1273	1279	higher
B-outcome	1280	1285	rates
I-outcome	1286	1288	of
I-outcome	1289	1290	"
I-outcome	1290	1292	No
I-outcome	1293	1304	significant
I-outcome	1305	1311	nausea
I-outcome	1311	1312	"
I-outcome	1313	1316	and
I-outcome	1317	1318	"
I-outcome	1318	1320	No
I-outcome	1321	1327	nausea
I-outcome	1327	1328	"
O	1329	1335	during
O	1336	1339	all
O	1340	1341	3
O	1342	1346	time
O	1346	1347	-
O	1347	1353	frames
O	1354	1357	and
O	1358	1364	better
O	1365	1368	QOL
O	1368	1369	.

O	1370	1377	Similar
O	1378	1386	findings
O	1387	1391	were
O	1392	1396	also
O	1397	1405	revealed
O	1406	1416	throughout
O	1417	1425	multiple
O	1426	1432	cycles
O	1432	1433	.

O	1434	1437	Pre
O	1437	1438	-
O	1438	1443	study
B-outcome	1444	1457	abnormalities
I-outcome	1458	1460	in
I-outcome	1461	1468	glucose
I-outcome	1469	1472	and
I-outcome	1473	1479	lipids
O	1480	1488	occurred
O	1489	1491	in
O	1492	1494	39
O	1494	1495	.
O	1495	1496	7
O	1496	1497	%
O	1498	1501	and
O	1502	1504	34
O	1504	1505	.
O	1505	1506	2
O	1506	1507	%
O	1508	1510	of
O	1511	1514	the
O	1515	1522	studied
O	1523	1533	population
O	1534	1546	respectively
O	1546	1547	;
O	1548	1553	there
O	1554	1558	were
O	1559	1561	no
O	1562	1573	differences
O	1574	1576	in
O	1577	1582	these
O	1583	1593	parameters
O	1594	1601	between
O	1602	1605	the
O	1606	1609	two
O	1610	1614	arms
O	1615	1617	at
O	1618	1621	end
O	1621	1622	-
O	1622	1624	of
O	1624	1625	-
O	1625	1630	study
O	1631	1641	assessment
O	1641	1642	.

O	1643	1646	The
O	1647	1655	addition
O	1656	1658	of
O	1659	1669	olanzapine
O	1670	1672	to
O	1673	1681	standard
O	1682	1692	aprepitant
O	1692	1693	-
O	1693	1698	based
O	1699	1709	antiemetic
O	1710	1717	regimen
O	1718	1726	provides
O	1727	1737	clinically
O	1738	1748	meaningful
O	1749	1760	improvement
O	1761	1763	in
O	1764	1775	controlling
O	1776	1780	CINV
O	1780	1781	.

O	1782	1786	This
O	1787	1790	was
O	1791	1801	associated
O	1802	1806	with
O	1807	1808	a
O	1809	1817	positive
O	1818	1824	impact
O	1825	1827	on
O	1828	1831	QOL
O	1832	1835	and
O	1836	1845	tolerable
O	1846	1854	toxicity
O	1855	1863	profiles
O	1864	1869	among
O	1870	1877	Chinese
O	1878	1884	breast
O	1885	1891	cancer
O	1892	1900	patients
O	1901	1910	receiving
O	1911	1922	doxorubicin
O	1922	1923	/
O	1923	1939	cyclophosphamide
O	1940	1952	chemotherapy
O	1952	1953	.

O	1954	1961	Further
O	1962	1969	studies
O	1970	1972	on
O	1973	1982	metabolic
O	1983	1991	profiles
O	1992	1994	of
O	1995	2001	breast
O	2002	2008	cancer
O	2009	2017	patients
O	2018	2021	are
O	2022	2031	warranted
O	2031	2032	.
